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Abstract
The ECFS-CTN Standardisation Committee has undertaken this review of lung clearance index as part of the group's work on evaluation of
clinical endpoints with regard to their use in multicentre clinical trials in CF.
The aims were 1) to review the literature on reliability, validity and responsiveness of LCI in patients with CF, 2) to gain consensus of the group
on feasibility of LCI and 3) to gain consensus on answers to key questions regarding the promotion of LCI to surrogate endpoint status.
It was concluded that LCI has an attractive feasibility and clinimetric properties proﬁle and is particularly indicated for multicentre trials in
young children with CF and patients with early or mild CF lung disease. This is the ﬁrst article to collate the literature in this manner and support
the use of LCI in clinical trials in CF.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V.
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1. Introduction
In the cystic fibrosis (CF) community, there is a need to
focus on developing and evaluating endpoints for clinical trials
in early disease. The European Cystic Fibrosis Society Clinical
Trial Network (ECFS-CTN) has established a Standardisation
Committee consisting of researchers with expertise in specific
outcome measures. The Standardisation Committee is under-
taking a rigorous evaluation of potential outcome measures for
multicentre clinical trials in CF. This article summarises the
group's work on lung clearance index (LCI).
A full description of the classification of outcome measures is
provided in the first document in the series of articles from the
ECFS-CTN Standardisation Committee (CFTR biomarkers
group) [1]. Briefly, outcome measures fall into three classes:
clinical endpoints, surrogate endpoints and biomarkers. Clinical
endpoints reflect how a patient feels, functions or survives and
detect a tangible benefit for the patient [2,3]. A surrogate endpoint
is a laboratory measurement used to predict the efficacy of therapy
when direct measurement of clinical effect is not feasible or
practical. Ideally, surrogate endpoints should shorten the period of
follow-up required. The link between the surrogate endpoint and
long-term prognosis must be proven. Forced expiratory volume in
one second (FEV1) is still the only accepted surrogate outcome for
the European Medicines Agency (EMA) and the North American
Food and Drug Association (FDA). A biomarker is defined as “a
Table 1
Definitions and justification for clinimetric properties.
Clinimetric
property
Definition Justification of importance
Reliability Degree to which a measurement is consistent and free from error Important to quantify error (systematic and random) so that true changes
can be discerned from changes due to normal fluctuations
Validity Concurrent validity: Degree to which a test correlates with a “gold
standard” criterion test which has been established as a valid test of the
attribute of interest
Convergent validity: Degree to which a test correlates with another test
which measures the same attribute
Discriminate validity: Degree to which a test differentiates between
groups of individuals known to differ in the attribute of interest
Predictive validity: Degree to which an attribute can be predicted using
the result of a predictor test/or degree to which prognosis can be predicted
The gold standard outcome measures are often not feasible. Therefore it is
important to know how an alternative outcomemeasure compares to the gold
standard, and how different outcome measures compare. It is important to
know the ability of outcome measures to discriminate between different
groups
Responsiveness Degree to which a test changes in response to an intervention known to
alter the attribute of interest
Important attribute of tests used in clinical practice or research to assess
treatment benefit (e.g. to identify improvements response to an intervention)
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characteristic that is objectively measured and evaluated as an
indicator of normal biologic processes, pathogenic processes or
pharmacologic response to a therapeutic intervention”. Bio-
markers are mainly used to explore proof-of-concept for a specific
compound. Some are currently being considered for “promotion”
to the status of surrogate endpoint.
Progression of lung disease in CF has slowed down [4], and
therefore FEV1 has become a less sensitive outcome measure.
LCI has repeatedly been shown to be superior to FEV1 to
monitor early CF lung disease when FEV1 is within normal
ranges [5,6]. It thus appears a good candidate to become a new
surrogate outcome measure in trials focusing on the early stages
of disease. LCI may also be useful clinically to monitor patients
with FEV1 within normal ranges, however this article focuses
on the use of LCI in clinical trials.
To gain acceptance of researchers and licensing bodies, an
endpoint must however have a body of supporting evidence
including acceptable clinimetric properties (Table 1) such as
reliability, validity and responsiveness to treatment, and
sufficient feasibility and safety. Clinimetric properties and
feasibility are population and situation dependent, therefore
data cannot readily be extrapolated to the CF population from
other disease populations.
The aims of this project were 1) to review the literature on
reliability, validity and responsiveness of LCI in patients with
cystic fibrosis, 2) to gain consensus of the group on the feasibility
of LCI and 3) to gain consensus on answers to key questions
regarding the promotion of LCI to surrogate endpoint status.
2. Methods
An exhaustive literature search was conducted in MEDLINE,
Allied and Complementary Medicine (AMED) and Embase using
the following combination of keywords: (“lung clearance index” or
“LCI” or “multiple breath washout” or “MBW” or “ventilation
inhomogeneity” or “sulphur hexafluoride” or “SF6” or “nitrogen
washout” or “helium washout” or “inert gas washout”) and “cystic
fibrosis”. The search was limited to full text articles in the English
language, with no limits on year of publication. A bibliography
search was also conducted of all included articles and relevant
reviews published until April 2013.
For clinimetric properties, data were extracted and tabulated
for reliability, validity, correlation with other outcome measures,
responsiveness and reference values. Definitions are given in
Table 1.
To evaluate feasibility, data were extracted and tabulated on
the proportion of attempts that were successful and reasons for
excluding tests. An expert panel also discussed the following
topics and reached consensus on each: risk involved, cost, ease of
performance, ease of administration, time to administer, equipment
and space needed and applicable age group. Specific advantages
and limitations of infant pulmonary function were also discussed.
Narrative answers to 4 key questions were discussed by the
expert panel during several face to face meetings
1) Does LCI have the potential to become a surrogate
outcome?;
2) For what kind of therapeutic trial is LCI appropriate?
(therapeutic aim, phase of trial, target population, number of
patients involved, number of sites involved);
3) Within what timeline can change be expected and what
treatment effect can be considered clinically significant?;
4) What are the most needed studies to further define LCI in
patients with CF and to explore its potential as a surrogate
marker? The consensus of the group is presented in the
current article.
After preparatory work over a period of 6 months,
participants with expertise in multiple breath washout met to
discuss and develop consensus on the four key questions and
feasibility (November 17 and 18, 2010, and June 9, 2011). The
manuscript was developed which reports both the systematic
review of clinimetric properties (performed by the core writing
team (LK, KDB, IS, PR)) and the expert panel's discussions
(four key questions and feasibility). This resulted in a draft
manuscript which was circulated to the group for review and
revision until group consensus was achieved.
3. Results
3.1. Use of LCI in clinical trials in CF
LCI derived from a multiple breath washout (MBW) provides
a global measurement of ventilation inhomogeneity. It reflects
abnormalities in ventilation in the respiratory tract compared to
normal, including the small airways which are affected early in
CF lung disease and where changes are not easily detected with
traditional pulmonary function techniques such as spirometry [7].
The ability to identify early airway dysfunction in these “silent
years”, when FEV1 is often within normal range, is of great
importance for investigating new therapies in infants and young
children and in those with mild disease [8]. LCI is beginning to be
used as an efficacy endpoint in CF clinical trials. It was the
primary outcome in a recent phase 2, multicentre trial of ivacaftor
in patients with the G551D mutation and normal lung function
[9]. It was used in single centre interventional studies of rhDNase
and hypertonic saline in infants and children with CF [10–12]. It
is one of the major secondary efficacy measures in the ongoing
UK CF Gene Therapy Consortium's large, placebo controlled,
multidose trial of non-viral gene therapy (http://clinicaltrials.gov
NCT01621867).
LCI is derived from a MBW technique which can be
performed either with inhalation of an inert tracer gas such as
sulphur hexafluoride (SF6) or helium, or by using 100% oxygen
to wash out resident nitrogen. The latter technique has been
available for several decades, takes slightly less time to perform
and is gaining increasing attention [13]. In the case of an
exogenous tracer, the gas is inspired until equilibrium is reached
(i.e. concentration of tracer is equal in both inhaled and exhaled
air). At this point the tracer gas source is removed and the
individual breathes room air until the concentration of the tracer
gas in exhaled air is 1/40th of the equilibrium concentration, an
arbitrary concentration based on the lower limits of detection
of the early nitrogen analysers. In the case of using nitrogen
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Table 2
LCI validity.
N and subject type Apparatus Gas Results for LCI Results for FEV1 Statistic Author
LCI discriminates patients with CF from non-CF subjects
71 CF Infants Mass spectrometer SF6 p = 0.002 p b 0.001* Unpaired t-test Hoo [21]
54 Non-CF
14 CF Infants Exhalyzer D a SF6 p = 0.022 NR NA Belessis [22]
NR Non-CF
39 CF Infants Mass spectrometer SF6 p b 0.001 p b 0.001* NR Lum [23]
21 Non-CF Infants 0.834 (0.05)
N = 22 (56%)
0.836 (0.05)*
N = 14 (36%)
Mean (SE) ROC;
N (%) individuals
with abnormal test
33 CF Infants Mass spectrometer SF6 Sensitivity (39.4%)
Specificity (94.3%)
NR Cross tabulation Haidopoulou [24]
(RPN)
35 Non-CF Infants AUCROC = 0.789
(0.68 to 0.90)
AUCROC
47 CF Infants and children Exhalyzer D a SF6 p b 0.001 NR NA Belessis [22]
25 Non-CF
30 Uninfected CF Infants and children p b 0.001
25 Non-CF
48 CF Preschool Mass spectrometer SF6 p b 0.001 p = 0.002 Unpaired t-test Aurora [35]
45 Non-CF p b 0.001*
48 CF Early school p b 0.001 p b 0.001
45 Non-CF p b 0.001*
73 CF Children Exhalyzer D a N2 p b 0.001 NR Unpaired t-test Singer [32]
(Pediatr Pulmonol)50 Non-CF
17 CF Children Mass spectrometer SF6 p b 0.001 NR NR Amin [11]
28 Non-CF Children
45 CF Children Mass spectrometer SF6 p b 0.001 NS MWUT Keen [40]
35 Non-CF Children
22 CF Children Mass spectrometer SF6 p b 0.001 p b 0.001 Unpaired t-test Aurora [30]
33 Non-CF Children Sensitivity = 95% Sensitivity = 50% Cross tabulation
Specificity = 97% Specificity = 100%
30 CF Children Mass spectrometer SF6 p b 0.001 p b 0.05* Unpaired t-test Aurora [33]
(AJRCCM)30 Non-CF Children Sensitivity = 77% Sensitivity = 7%*
56 CF Children Mass spectrometer SF6 p b 0.001 p b 0.001 NR Owens [25]
52 Non-CF Children
43 CF Children (b18 yrs) Mass spectrometer SF6 p b 0.001 NS Unpaired t-test Gustafsson [26]
(ERJ)28 Non-CF
60 CF Children Mass spectrometer SF6 Sensitivity (76.7%)
Specificity (96.8%)
NR Cross tabulation Haidopoulou [24]
(RPN)
62 Non-CF Children AUCROC = 0.94
(0.89 to 0.98)
AUCROC
5 CF Children Modified Innocor b SF6 p = NS NR Wilcoxson Pittman [41]
10 Non-CF
68 CF Children EasyOne Pro c SF6 p b 0.001 NR NR Fuchs [42]
(JCF)38 Non-CF
18 CF Children Modified Innocor b SF6 p = 0.022 NS Unpaired t-test Horsley [16]
(RPN)29 Non-CF Children
15 CF Children Exhalyzer D a He p b 0.001 NR Unpaired t-test Bakker [43]
15 Non-CF Children
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26 CF Children b18 yrs Spiroson d SF6 p b 0.001 p b 0.01 Unpaired t-test Fuchs [31]
22 Non-CF Children b18 yrs
10 CF Children b10 yrs p = 0.009 NS
8 Non-CF Children b10 yrs
Specificity = 100% Specificity = 100%*
AUCROC = 0.95 (0.03)
p b 0.001
AUCROC = 0.66 (0.07)
p b 0.05*
p b 0.001 NS
139 CF Children and adults EasyOne Pro c SF6 p b 0.001 p b 0.001 Unpaired t-tests Fuchs [20]
(Pediatr Pulmonol)102 Non-CF
11 CF Children and adults N2 analyser N2 p b 0.01 p b 0.001 ANOVA Gustafsson [19]
15 Asthma Children
18 Non-CF Children
25 CF Adults N2 analyser N2 p b 0.001 p b 0.001 Unpaired t-test Verbanck [17]
(ERJ)25 Non-CF
22 CF Adults Modified Innocor b SF6 p b 0.0001 p b 0.0001 Unpaired t-test Horsley [16]
(RPN)17 Non-CF Adults
33 CF Adults Modified Innocor b SF6 p b 0.001 p b 0.001 MWUT Horsley [18]
(Thorax)48 Non-CF Adults
N and subject type Apparatus Gas Comparison Results for LCI Results for FEV1 Statistic Author
LCI differs between patients with CF who have different phenotypes
47 CF Infants
and children
Exhalyzer D a SF6 With vs. without P. aeruginosa p = 0.038 NA NR Belessis [22]
With vs. without infection NS NA
27 CF Infants
and children
Exhalyzer D a SF6 P. aeruginosa vs. other pathogen p b 0.01 NA
49 CF Infants
and children
Exhalyzer D a SF6 With vs without bronchiectasis NS NR MWUT Hall [27]
With vs without air trapping NS NR
30 CF Children Mass spectrometer SF6 With vs without P. aeruginosa p b 0.05 NS Unpaired t-test Aurora [8]
(AJRCCM)
22 CF Children Mass spectrometer SF6 With vs without P. aeruginosa p b 0.05 NS Unpaired t-test Aurora [30]
43 CF Children
(b18 yrs)
Mass spectrometer SF6 CF with bacterial colonisation vs. CF
without bacterial colonisation
p b 0.01 p b 0.001 Unpaired t-test Gustafsson
[26]
(ERJ)
28 Non-CF
152 CF Children Pediatric
Pulmonary Unit e
N2 No infection vs. SA vs. PA vs. SA+PA p b 0.0001 NR Linear mixed
effect model
Kraemer [44]
(Resp Res)
18 CF Children Modified Innocor b SF6 Adults vs. children p b 0.0001 NR Unpaired t-test Horsley [16]
(RPN)22 CF Adults
LCI is a more sensitive indicator of abnormalities than FEV1
47 CF Infants
and children
Exhalyzer D a SF6 Detection of P. aeruginosa 0.819 (0.686 to
0.951),
p = 0.004
NA AUC (95%CI) Belessis [22]
Sensitivity = 67%
Specificity = 80%
PPV = 47%
NPV = 93%
NA Sensitivity
Specificity
(%)
49 CF Infants
and children
Exhalyzer D a SF6 Extent of bronchiectasis on HRCT NS NR Multivariate regression
coefficient
Hall [27]
(continued on next page)
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Table 2 (continued)
N and subject type Apparatus Gas Comparison Results for LCI Results for FEV1 Statistic Author
43 CF Children Mass spectrometer SF6 LCI(+)/FEV1(+) n = 9 NA Number subjects
(+=abnormal; −=
normal)
Gustafsson
[26]
(ERJ)
LCI(+)/FEV1(−) n = 18
LCI(−)/FEV1(−) n = 15
LCI(−)/FEV1(+) n = 1
28 Non-CF Children LCI(+)/FEV1(+) n = 0
LCI(+)/FEV1(−) n = 0
LCI(−)/FEV1(−) n = 28
LCI(−)/FEV1(+) n = 0
53 CF Children Mass spectrometer SF6 Concordance with abnormal Brody-II
HRCT
39/53 (74%) 18/57 (32%) Number (%) subjects Owens [25]
Total concordance with Brody-II HRCT
result (both abnormal and normal)
81% 47%
44 CF Children
and adults
Mass spectrometer SF6 Abnormal when structural abnormalities on
HRCT
Bronchiectasis
Sensitivity = 85
(71 to 98)%
Specificity = 50
(27 to 73)%
Bronchiectasis
Sensitivity = 19 (4 to 34)%
Specificity = 89
(74 to 100)%
Sensitivity and
specificity % (95%CI)
Gustafsson
[28]
HRCT Score
Sensitivity = 93
(83 to 100)%
Specificity = 65
(42 to 87)%
HRCT Score
Sensitivity = 26 (9 to 42)%
Specificity = 100
(100 to 100)%
Air trapping
Sensitivity = 94
(82 to 100)%
Specificity = 43
(25 to 61)%
Air trapping
Sensitivity = 25 (4 to 46)%
Specificity = 89
(78 to 100)%
34 CF Children
and adults
EasyOne Prof SF6 Concordance with Bhalla CT Score 28/34 (82.3%) NA (sample of patients with
normal FEV1)
Number (%) patients Ellemunter
[29]
Abnormal when structural
abnormalities on HRCT
Sensitivity = 88
(69 to 97)%
Specificity = 63
(26 to 90)%
PPV = 88%
NPV = 63%
NA (sample of patients with
normal FEV1)
Sensitivity and
specificity % (95% CI)
* = FEV0.5.
aLCI = alveolar lung clearance index, CF = cystic fibrosis, FEV1 = forced expiratory volume in one second, LCI = lung clearance index, LCI(+) = abnormal LCI, LCI(−) = normal LCI; FEV1(+) = abnormal FEV1;
FEV1(−) = normal FEV1, MES = modified emission spectro-photometer, NA = not applicable, NR = not reported, NS = not significant, SA = Staphylococcus aureus, PA = Pseudomonas aeruginosa; MS = mass
spectrometer; USFS = ultrasonic flow sensor.
a Exhalyzer D (Ecomedics AG, Duernten, Switzerland).
b Modiﬁed Innocor (Innovision, Odense, Denmark).
c EasyOne Pro, MBW Module (ndd Medizintechnik AG, Zurich, Switzerland) plus addition of CO2 analyser (DUET ETCO2 Module, Welch Allyn OEM Technologies, Beaverton, OR, USA).
d Spiroson (ndd Medical Technologies) plus addition of CO2 analyser (DUET ETCO2 Module, Welch Allyn OEM Technologies, Beaverton, OR).
e Pediatric Pulmonary Unit (SensorMedics 220, Yorba Linda,CA, USA).
LCI is a more sensitive indicator of abnormalities than FEV1
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washout, which is a resident gas, 100% oxygen is delivered until
mean expired nitrogen concentration falls below 1/40th of the
original concentration. In both methods, LCI is calculated as the
cumulative expired volume during the washout phase divided by
the functional residual capacity (FRC) i.e. the number of FRC
volume turnovers required to clear the tracer gas. FRC is derived
from the cumulative exhaled marker gas concentration divided by
the difference in end-tidal gas concentration at the start of the
washout and the end-tidal concentration at the end of the
washout. Individuals with greater ventilation inhomogeneity use
a greater number of turnovers to clear the tracer gas and therefore
will have a higher (more abnormal) LCI.
Many different systems have been or are being used to
measure MBW in clinical trials in CF. For detailed guidelines
about washout equipment specifications, test performance and
data analysis we refer to a recent ERS/ATS consensus document
[14]. Although the mass spectrometer is considered the gold
standard gas analyser equipment, it is very expensive, custom
built for MBW and therefore not suitable for widespread use [14].
The majority of published results to date are calculated by offline
analysis using proprietary software. The use of the software
requires training and there is an element of subjectivity in reading
the results. For LCI to be used as an outcome measure in
large-scale multicentre trials, it is necessary to implement a file
transfer and central reading facility. Only with such measures can
variability be reduced. Commercially available systems, compli-
ant with the above ERS guidelines will provide the opportunity to
standardise the procedure in future multicentre trials. The online
Table E1 lists the currently commercially available apparatuses
and some of their characteristics. Results from MBW tests using
different gases are not interchangeable, e.g. on average, LCI
determined by nitrogen washout is higher than LCI determined
by washout of SF6 [15]. Traditionally, the mean of 3 (or at least 2)
valid LCI measurements with FRC not differing more than 10%
have been reported. The recent ERS document describes
acceptability criteria in great detail [14]. If all other criteria are
met, the new advice is to only reject tests where FRC differs by
N25% from the median values across the 3 tests. Most published
studies pre-date this advice and have used a 10% criterion.
Throughout the tables we will refer to the apparatus used to
obtain the MBW measurements. Since most of the reported
studies predate the ERS consensus, all necessary information is
not always available.
3.2. Clinimetric properties of LCI
3.2.1. Reliability (Table E2 online)
The majority of studies on reliability were conducted in
children, with fewer in infants and adults. In most reports, the
mean coefficient of variation (CV) for LCI measurements
within one session was low (between 3 and 7%) but the range
was higher. A mean CV above 10% was reported in a study in
children with CF using an Innocor with a closed circuit.
Therefore this apparatus set-up is not recommended [14]. Both
CV and ICC of measurements within one session were as
acceptable in CF as in healthy controls. One study showed
neither a significant nor systematic difference in LCI between
repeated sessions of LCI measurements. A low variability
between repeated sessions of LCI measurements has also been
reported by others: mean CV of up to 9 % in the short and
medium term and high intra-class correlation coefficients.
3.2.2. Validity (Table 2)
Overall, 22 out of 23 studies demonstrated the ability of LCI to
discriminate between individuals with CF and healthy, non-CF
subjects. Of these, 3 studies included adults only [16–18], the
others included either children and adults (n = 2) [19,20], or
children only (n = 18 studies including 4 studies also in infants
[21–24]). Several studies demonstrated the ability of LCI to
discriminate between groups of patients with CF and differing
degrees of lung disease based on age, infection status or structural
changes on high resolution computerized tomography (HRCT) of
the chest. In this respect LCI is superior to FEV1. In infants and
children, six studies compared the sensitivity of LCI and FEV1 as
indicators of structural lung abnormalities demonstrating that for
bronchiectasis and air trapping on HRCT, LCI is more sensitive
but less specific than FEV1 [22,25–29].
3.2.3. Correlation with other outcomes (Table 3)
Twenty one studies have examined the relationship between
LCI and other outcome measures with the majority of studies
focusing on FEV1 and HRCT. In 10 studies in children and/or
adults with CF, a significant but variable correlation between LCI
and FEV1/FEV0.5 was demonstrated [16–18,20,21,29–33]. One
study in preschool children reported a correlation with FEV0.5,
FEF25–75 and sRaw. These studies also pointed out that LCI is
superior in detecting abnormalities. In infants with CF diagnosed
via newborn screening (mean age 11 weeks) there was no
correlation between LCI and FEV0.5 [21]. In a mixed group of
infants and toddlers (including two with CF), LCI correlated with
the volume of trapped gas (expressed as percent of FRC) [34].
Abnormal LCI was shown to have amoderate to strong correlation
with structural abnormalities evaluated separately or using global
HRCT scores. Overall, correlation was good between LCI and
bronchial wall thickening, mucus plugging and bronchiectasis, but
weaker with air trapping. LCI was also shown to correlate with
other outcome measures including, age, onset of infection, type of
infection, inflammation measured in the bronchoalveolar lavage
fluid, blood gas analysis, exhaled nitric oxide fraction, capno-
graphic parameters, and symptom score.
3.2.4. Predictive validity (Table E3)
One study demonstrated the validity of LCI in preschool
children as a predictive test of abnormal lung function at an early
school age. Whilst positive predictive values for future ab-
normalities were also good for FEV1, LCI had a stronger negative
predictive value [35]. Further studies to investigate the relation-
ship between LCI measurements and the long term course of CF
(lung function, exacerbations etc.) are urgently required.
3.2.5. Responsiveness (Table 4)
Several studies provide information on responsiveness of LCI
in small numbers of patients (range n = 11 to 38). In patients with
CF, LCI was able to detect a treatment effect after four weeks of
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Table 3
Cross sectional correlation between LCI and other measures.
N and subject type Apparatus Gas Comparison Result Statistic Author
In children and adults with CF, LCI correlates with specific spirometry parameters such as FEV1 and MEF25
22 CF Children Mass spectrometer SF6 FEV1 r
2 = −0.62, p b 0.0005 Linear regression Aurora [30]
1 MEF25 r
2 = −0.46, p b 0.001
26 CF Children Spiroson a SF6 FEV1 r = −0.476, p = 0.014 Spearman correlation coefficient Fuchs [31]
2 MEF25 r = −0.523, p = 0.006
139 CF Children and
adults
EasyOne Pro b SF6 FEV1 z-score p b 0.001 NR Fuchs [20]
(Pediatr Pulmonol)3 MEF25 p b 0.001
34 CF Children and
adults
EasyOne Pro b SF6 FEV1 r = 0.468, p = 0.005 Pearson correlation coefficient Ellemunter [29]
4
33 CF Adults Modified Innocor c SF6 FEV1 r
2 = 0.69, p b 0.001 Linear regression Horsley [18]
(Thorax)5
40 CF Adults and
children
Modified Innocor c SF6 FEV1 z-score r = −0.86, p b 0.0001 Spearman correlation coefficient Horsley [16]
(RPN)6 Curvilinearity of washout tracing r = −0.88, p b 0.0001
22 CF Adults RV/TLC r = 0.73, p b 0.0002
25
7
CF Adults N2 analyser N2 FEV1 r = −0.76, p b 0.001 Spearman correlation coefficient Verbanck [17]
(ERJ)
73 CF Children Exhalyzer D e N2 FEV1 z-score r = −0.49, p b 0.001 Pearson correlation coefficient Singer [32]
(Pediatr Pulmonol)FEV1/FVC z-score R = −0.44, p = 0.003
FEF25–75 z-score R = −0.51, p b 0.001
In preschool children with CF, LCI correlates with FEV0.5, FEF25–75 and sRaw
30 CF Children
2–5 yrs
Mass spectrometer SF6 sRaw r
2 = −0.14, p = 0.04 Linear regression Aurora [8] (AJRCCM)
FEV0.5 r
2 = 0.21, p = 0.01
FEF25–75 r
2 = 0.28, p = 0.003
In infants with CF detected after newborn screening, LCI did not correlate with FEV0.5
71 CF Infants after
NBS
Mean age
11 wks
Mass spectrometer SF6 FEV0.5 NS Pearson correlation coefficient Hoo [21]
In a mixed group of infants and toddlers (including 2CF), LCI correlated with the proportion of trapped gas
8 3 risk of atopy
3 ex-premie
2 CF With and without
respiratory disease
Children Mass spectrometer SF6 VTG, SF6/FRC r
2 = 0.94, p b 0.001 Linear regression Gustafsson [26]
(Pediatr Pulmonol
35:42–49)
LCI correlates well with parameters derived from imaging analysis.
49 CF Infants and
children
Exhalyzer D e SF6 Extent of bronchiectasis on HRCT NS Spearman correlation coefficient Hall [27]
Extent of air trapping on HRCT r = 0.31, p = 0.03
57 CF Children Mass spectrometer SF6 Brody-II HRCT total score r = 0.77 Spearman correlation coefficient Owens [25]
Brody-II bronchiectasis score r = 0.71
Brody-II peribronchial
thickening score
r = 0.72
Brody-II mucous plugging
score
r = 0.67
Brody-II air trapping score r = 0.58
34 CF Children and
adults
EasyOne Pro b SF6 Bhalla HRCT score r = −0.54, p = 0.001 Pearson correlation coefficient Ellemunter [29]
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44 CF Children and
adults
Mass spectrometer HRCT scores r = 0.65 to 0.85 Spearman correlation coefficient Gustafsson [28]
26 CF Children Spiroson a SF6 Crispin-Norman X-ray score r = 0.684, p = 0.001
No sig. correlation
between CN score and FEV1
*
Spearman correlation coefficient Fuchs [31]
LCI correlates with some other parameters of disease severity
71 CF Infants Mass spectrometer SF6 Homozygous F508del NS Linear regression Hoo [21]
Respiratory symptoms NS
Positive growth (cough swab) NS
Antibiotics NS
47 CF Infants and
children
Exhalyzer D e SF6 LCI vs. pathogen load
CFU/mL)
R2 = 0.10, p = 0.031 Linear regression Belessis [22]
LCI vs. IL-8 R2 = 0.20, p = 0.004
LCI vs. neutrophil count R2 = 0.21, p = 0.001
73 CF Children Exhalyzer D e N2 P. aeruginosa infection status r = 0.75, p b 0.001 Pearson correlation coefficient Singer [32]
(Pediatr Pulmonol)PaO2 r = −0.54
142 CF Children Pediatric Pulmonary Unit f N2 Age F = 22, p b 0.0001 Linear mixed effect model Kraemer [45]
Age at onset of chronic PA
infection
F = 4.2, p = 0.02
CFTR genotype NS
178 CF Children Pediatric Pulmonary Unit f N2 PaO2 b80 mm Hg t-Statistic = −3.156, p = 0.002 Linear mixed model, adjusted by
year at testing
Kraemer [46]
(Respiratory
Research)PaO2 above or below 80 mm Hg χ
2 = 9.644, p = 0.002 Chi square
15 CF Children Exhalyzer D e He LCI vs. Mean nocturnal oxygen
saturations
NS Spearman correlation coefficient Bakker [43]
LCI vs. Mean cough (cough s/h) NS
15 Non-CF Children LCI vs. mean nocturnal oxygen
saturations
NS
LCI vs. Mean cough
(cough s/h)
NS
68 CF Children and adults EasyOne Pro b SF6 Slope 2 of CO2 expirogram r = −0.198, p b 0.042 Pearson correlation coefficient Fuchs [42] (JCF)
Slope 3 of CO2 expirogram r = 0.376, p b 0.001
Capnographic index (KPIv) r = 0.610, p b 0.001
45 CF Children Mass spectrometer SF6 FENO50 r = −0.43, p = 0.003 Spearman correlation coefficient Keen [40]
Alveolar NO r = −0.32, p = 0.037
FENO50 β = −0.251
95%CI: −0.354 to −0.147,
p b 0.001
Multiple regression model
(dependent variable: log FENO50)
28 CF Children Vmax 22D
d N2 Change in CFCS in response to
IVAB
r = 0.48, p = 0.01 NR Robinson [36]
(Pediatr Pulmonol)
CFU = colony forming units; FEF25–75 = mean forced expiratory flow between 25 and 75% of exhaled vital capacity; FENO50 = fractional exhaled nitric oxide, measured at a flow rate of 50 ml/s; FEVx = forced
expiratory volume in x seconds; HRCT = high resolution computed tomography; IVAB = intravenous antibiotics; MEF25 = forced expiratory flow where 25% of the FVC remains to be expired; NS = not significant;
USFS = ultrasonic flow sensor; NR = not reported; RV/TLC = ratio of residual volume to total lung capacity; sRaw = specific airway resistance measured by body plethysmography; VTG, SF6/FRC = volume of
trapped gas as measured with sulphur hexafluoride as tracer gas.
a Spiroson (ndd Medical Technologies) plus addition of CO2 analyser (DUET ETCO2 Module, Welch Allyn OEM Technologies, Beaverton, OR, USA).
b EasyOne Pro, MBW Module (ndd Medizintechnik AG, Zurich, Switzerland) plus addition of CO2 analyser (DUET ETCO2 Module, Welch Allyn OEM Technologies, Beaverton, OR, USA).
c Modiﬁed Innocor (Innovision, Odense, Denmark).
d Vmax 22D spirometer and Spectra software (SensorMedics Corp., Yorba Linda, CA, USA).
e Exhalyzer D (Ecomedics AG, Duernten, Switzerland).
f Pediatric Pulmonary Unit (SensorMedics 220, Yorba Linda, CA, USA).
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Table 4
Responsiveness of LCI in cystic fibrosis.
N Subject type Apparatus Gas Intervention LCI results
(mean SD)
Did other endpoints
detect difference?
Statistic Author
LCI decreases after 2 weeks treatment with IV antibiotics, and after 4 weeks treatment with hypertonic saline and rhDNase in patients with cystic fibrosis
16 Children Easyone Pro a SF6 Endurance training
and flutter/PEP
p = NS
pre-ACT: 7.76 (1.23), post-ACT: 7.96 (1.04)
NS Paired t Fuchs [47]
(Pediatr Pulmonol)
11 Children and adults MESb N2 Salbutamol, 5 mg once p = NS Sacin p b 0.01
FEV1 p b 0.01
Paired t Gustafsson [19]
20 Children Mass spectrometer SF6 7% hypertonic saline,
4 ml BID 4 wk
vs.
Isotonic saline,
4 ml BID 4 wk
p = 0.016
Rx effect: 1.16 (0.94), 95% CI [0.27 to 2.05]
HTS: pre: 8.84 (1.95), post: 7.86 (1.71)
ITS: pre: 8.71 (2.10), post: 8.89 (2.10)
No (spirometry NS) Repeated measures ANOVA Amin [10]
17 Children Mass spectrometer SF6 rhDNase, 2.5 ml QD 4 wk
vs.
Placebo, 2.5 ml QD 4 wk
p = 0.02
Rx effect: −0.90 (1.44)
rhDNase: pre: 8.31 (1.48), post: 7.69 (1.65)
Placebo: pre: 8.75 (1.72), post: 8.52 (1.19)
FEF25–75%pred p = 0.03
FEF25–75
z-score p = 0.03
Mixed model Amin [11]
28 Children Vmax 22D
c N2 IV antibiotics p = 0.03
Rx effect: 3.8% decrease
Admission: 10.10 range [6.87 to 14.83]
Discharge: 9.62 range [7.37 to 13.45]
CFCS p b 0.01
FEV1 p b 0.01
FVC p b 0.01
RV/TLC p b 0.05
VO2peak p b 0.05
Paired t-test Robinson [7]
38 Adults Innocor d SF6 IV antibiotics p = 0.003
Rx effect: −0.8 (1.4)
Start IVAB: 14.6 (2.7)
End IVAB: 13.8 (2.4)
Yes e Paired t-test Horsley [37]
Abbreviations: CFCS = cystic fibrosis clinical score, FEV1 = forced expiratory volume in 1 s, FVC = forced vital capacity, IQR = interquartile range, MES = modified emission spectrophotometer, NS = not
significant; RV/TLC = residual volume to total lung capacity ratio, Sacin and Scond additional LCI parameters (for more info see review, Robinson [7]), wk = weeks.
a EasyOne Pro, MBW Module (ndd Medizintechnik AG, Zurich, Switzerland) plus addition of CO2 analyser (DUET ETCO2 Module, Welch Allyn OEM Technologies, Beaverton, OR, USA).
b Medscience 505 (Medscience Electronics, Inc., St. Louis, MO, USA).
c Vmax 22D spirometer and Spectra software (SensorMedics Corp., Yorba Linda, CA, USA).
d Modiﬁed Innocor (Innovision, Odense, Denmark).
e Large number of endpoints explored: in general clinical observations, symptom scores, lung function, serum inﬂammatory markers and some structural endpoints improved.
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inhalation of dornase alpha [10], four weeks of inhalation of
hypertonic saline [11] and after a course of intravenous
antibiotics for a respiratory exacerbation [10,11,36,37]. One
short term study did not show a statistically significant treatment
effect with 5 mg of inhaled salbutamol as measured by LCI in 11
children and adults with CF. Only Sacin improved, an index
derived from MBW which reflects inhomogeneity in the airways
close to or within the gas exchange zone [19]. It may not be
surprising that LCI did not detect change; bronchodilators target
larger airways whereas LCI is considered to be more reflective of
ventilation homogeneity in smaller airways. There is also little
information on the efficacy of inhaled bronchodilator therapy in
CF using other outcome measures.
3.2.6. Reference values (Table 5)
Reported reference values predate the ERS guideline. We list
the reported reference ranges according to gas used, set-up used
and age category. It is important to note that reference values are
dependent on age of participants, method of analysis (i.e. online
vs. offline), software used, device and set-up and tracer gas used.
Reference values are not interchangeable between different
methods. In addition, we refer to an abstract containing reference
values for commercially available equipment over a wide age
range [38].
3.2.7. Feasibility of LCI (Table E4)
Feasibility data were collated from studies in CF, and are
mainly from children; fewer studies have been conducted in adults
or infants. In children, success rates ranged from 24% to 100%.
The study with the lowest success rates was evaluating feasibility
in the clinical setting in which strict time constraints were imposed
(20 min for participant familiarisation and performance of
measurement). This is not as relevant in clinical trials as there
tends to be more time for participant familiarisation and per-
formance of repeat measures [32]. In infants and preschool
children, success rate can be lower. Common reasons for exclusion
of tests includemanoeuvres that are not technically acceptable (e.g.
unstable breathing pattern) or lack of within-session reproducibil-
ity (i.e. no two curves within 10% for FRC measurement). The
experience of several hundred LCI measurements in adults with
CF in the UK CF Gene Therapy Consortium gene therapy studies
indicates feasibility in this group of close to 100% (unpublished
observations).
3.3. Group consensus on feasibility
MBW is a safe technique since it uses either oxygen for
nitrogen washout or very low concentrations of inert tracer
gases SF6 and helium.
For young children, quiet breathing is performed using a
face mask, whereas for older children and adults, a mouth piece
is used. In neonates the test can be attempted during natural
sleep. This is usually impossible beyond the neonatal period.
Few have embarked on LCI measurements in children under
the age of three years, especially beyond the newborn period.
From experience with other lung function tests, it is anticipated
that the test duration and the need for regular and quiet breathing
will imply sedation. As for any test done under sedation this
requires close monitoring and is associated with a small risk. In
infants with rapid breathing rates, the gas analyser must have a
rapid response time. Commercial stand alone SF6 analysers can
be adapted to provide the rapid response times necessary to
measure LCI in infants. Most studies in infants have used a mass
spectrometer. The nitrogen washout technique has not yet been
validated in infants in whom the impact of breathing 100%
oxygen on ventilation pattern should be further explored.
In infants and preschoolers, MBW is simpler than forced
expiratory techniques. MBW requires only quiet tidal breathing
whereas the raised volume rapid thoraco-abdominal compression
(RVRTC) technique requires high skill, long term and continuous
training and numerous acceptability criteria. RVRTC feasibility
in infants has a much lower feasibility than LCI when comparing
the percent of successful measurements (albeit between studies).
A large multicentre trial evaluating feasibility in RVRTC also
showed that feasibility was much lower in naive centres com-
pared to more experienced ones, demonstrating the dependence
on training and experience [67].
MBW takes more time than routine spirometry. In general,
three repeat measurements are performed to generate a single
mean value. In healthy subjects, both phases take approxi-
mately less than 5 min. Both wash-in and wash-out require less
time in healthy subjects than in people with obstructive
airways disease. The time needed increases relative to the
increase of LCI. The nitrogen wash-out technique has the
advantage of being shorter, as a wash-in is not needed before
the 1st washout. The time the patient is attached to the
equipment is also reduced since all wash-in phases are done
with room air. Time requirements also increase when off-line
analysis is used, however automated calculation of LCI from
the MBW tracer helps to reduce analysis time. The manpower
required increases when testing infants and young children, as
at least two people are needed.
The equipment (hardware and software) and consumables
required depend on the technique used [14]. In general the
following should be considered; a trolley-mounted analyser or
mass spectrometer, space for the tracer gas cylinder, a seat for the
individual, a TV/DVD for distraction and a computer with software
for data storage and analysis. These can easily be accommodated in
most lung function laboratories. Tracer gas build-up in confined
spaces should be prevented by good ventilation of the test room. In
multicentre studies, the tracer gas used must be approved by all
national authorities, which may limit the use of SF6.
Ongoing developments may further improve LCI feasibility;
assessing whether results from partial washout (first breaths)
predict the ‘standard’ LCI value. The additional value of other
indices derived fromMBW, such as Sacin and Scond, that describe
the site of ventilation inhomogeneity, are being explored.
3.4. The “four key questions”
3.4.1. Question 1: Does LCI have the potential to become a
surrogate outcome parameter?
LCI is potentially very valuable as a surrogate outcome
parameter. It reflects disease in the peripheral airways which
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Table 5
Reference values for LCI in healthy controls according to inert gas, age and apparatus used.
N Age group Additional info Apparatus Mean LCI
Median*
SD
SE*
Range
IQR*
95% CI Upper limit of normality Author
SF6
201 Infants Exhalyzer D a 6.6* NR 5.5 to 8.6 NR NR Kieninger [48]
29 Infants Preterm
Time 1
Exhalyzer D a 7.3 NR 6.0 to 10.3 NR NR Sinhal [49]
29 Infants Preterm
Time 2
Exhalyzer D a 7.5 NR 6.3 to 10.6 NR NR Sinhal [49]
64 Infants Full term Exhalyzer D a 7.17 0.54 NR NR NR Hülskamp [50]
59 Infants Preterm Exhalyzer D a 7.14 0.88 NR NR NR Hülskamp [50]
16 Infants Full term Exhalyzer D a 6.51 0.27 NR NR NR Riedel [51]
14 Infants Preterm Exhalyzer D a 6.54 0.49 NR NR NR Riedel [51]
20 Infants Facemask Exhalyzer D a 6.6 0.8 NR NR NR Schulzke [52]
20 Infants Nosemask Exhalyzer D a 7.2 0.9 NR NR NR Schulzke [52]
25 Infants and children Exhalyzer D a 6.45 0.49 5.42 to 7.37 7.41 Belessis [22]
39 Children Exhalyzer D a 5.5* NR 4.2 to 6.8 NR NR Kieninger [48]
185 Infants Full term Spiroson b 7.0 0.8 5.5 to 10.1 NR NR Latzin [53]
239 Infants Preterm Spiroson b 6.9 0.7 5.2 to 8.5 NR NR Latzin [53]
22 Children Spiroson b 6.7 0.5 5.8 to 7.6 NR 7.77 Fuchs [31]
9 Adults Spiroson b 7.10 0.30 NR NR NR Fuchs [54]
10 Adults Supine Spiroson b 5.63 0.43 NR NR NR Riedel [55]
10 Adults Prone Spiroson b 7.13 0.64 NR NR NR Riedel [55]
10 Adults Left lateral lying Spiroson b 6.27 0.44 NR NR NR Riedel [55]
10 Adults Right lateral lying Spiroson b 6.65 0.52 NR NR NR Riedel [55]
22 Children (b18y) Hannover EasyOne Pro c 6.13 0.3 5.57 to 6.64 NR 7.0 Fuchs [56]
22 Children (b18y) Innsbruck EasyOne Pro c 6.27 0.5 5.36 to 7.06
102 Children and adults EasyOne Pro c 6.3 0.19 NR NR NR Fuchs [20] (Pediatr Pulmonol)
10 Children Modified Innocor d 5.98 1.22 3.74 to 7.53 NR NR Pittman [41]
29 Children Modified Innocor d 6.24 0.47 5.14 to 7.05 NR NR Macleod [57]
12 Children Modified Innocor d 6.3 0.5 5.6 to 7.1 NR 7.3 Horsley [18]
(Thorax)
29 Children Modified Innocor d 6.2 0.5 5.1 to 7.1 NR 7.5* Horsley [16]
(RPN)
48 Adults Modified Innocor d 6.7 0.4 6.0 to 7.8 NR 7.5 Horsley [18]
(Thorax)
17 Adults Modified Innocor d 6.7 0.6 5.9 to 7.9 NR 7.5* Horsley [16]
(RPN)
ULN calculated from combined
sample of adults and children*
21 Infants Mass spectrometer 7.2 0.3 NR NR 7.8 Lum [23]
45 Preschool Mass spectrometer 6.69 0.5 NR NR Aurora [35]
45 Early school Mass spectrometer 6.67 0.5 NR NR Aurora [35]
28 Children Mass spectrometer 6.13 0.41 NR NR 6.95 Amin [11]
72 Children Mass spectrometer 6.6* NR 6.5 to 6.7* NR NR Sonnappa [58]
35 Children Mass spectrometer 5.9* NR 5.1 to 7.8 NR NR Keen [40]
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31 Children Mass spectrometer 6.89 0.44 NR 7.77 Aurora [8] (AJRCCM)
33 Children Mass spectrometer 6.45 0.49 NR NR 7.41 Aurora [40]
28 Children (b18 yrs) Mass spectrometer 6.33 0.43 NR NR 7.17 Gustafsson [26] (ERJ)
52 Children Mass spectrometer 6.6 0.5 NR NR 7.5 Owens [25]
9 Adults Mass spectrometer 7.21 0.26 NR NR NR Fuchs [54]
11 Adults Standing,
VT of 750 ml
Mass spectrometer 7.10 0.17* NR NR NR Grönkvist [59]
11 Adults Standing,
VT of 1000 ml
Mass spectrometer 7.05 0.15* NR NR NR Grönkvist [59]
11 Adults Standing,
VT of 1250 ml
Mass spectrometer 7.05 0.17* NR NR NR Grönkvist [59]
11 Adults Supine,
VT of 750 ml
Mass spectrometer 6.95 0.16* NR NR NR Grönkvist [59]
11 Adults Supine,
VT of 1000 ml
Mass spectrometer 7.07 0.16* NR NR NR Grönkvist [59]
11 Adults Supine,
VT of 1250 ml
Mass spectrometer 7.23 0.18* NR NR NR Grönkvist [59]
N Age group Additional info Apparatus Mean LCI
Median*
SD
SE*
Range
IQR*
95% CI Limits of normality Author
N2
50 Children Healthy Exhalyzer D a 6.1 0.9 NR NR 7.9 Singer [32]
20 Pre-term infants Healthy N2 analyser 10.8 1.4 NR NR NR Shao [60]
32 Infants Preterm N2 analyser 11.3 2.05 NR NR NR Hjalmarson [61]
53 Infants Full-term N2 analyser 10.2 1.82 NR NR NR Hjalmarson [61]
60 Adults Female N2 analyser 6.26 0.44 NR NR NR Verbanck [62]
60 Adults Male N2 analyser 6.28 0.39 NR NR NR Verbanck [62]
30 Adults Female N2 analyser 5.77 0.50 NR NR NR Verbanck [62]
30 Adults Male N2 analyser 5.65 0.49 NR NR NR Verbanck [62]
17 Adults N2 analyser 7.02 0.6 NR NR NR Downie [63]
10 Adult Female N2 analyser 7.6 1.0 NR NR NR Arborelius [64]
11 Adult Male N2 analyser 7.5 0.9 NR NR NR Arborelius [64]
12 Children Sitting MES e 6.39 0.36 NR NR NR Gustafsson [26] (Pediatr Pulmonol 36:34–42)
12 Children Supine (0 min) MES e 6.31 0.56 NR NR NR Gustafsson [26] (Pediatr Pulmonol 36:34–42)
12 Children Supine (30 min) MES e 6.29 0.47 NR NR NR Gustafsson [26] (Pediatr Pulmonol 36:34–42)
12 Children Supine (60 min) MES e 6.39 0.43 NR NR NR Gustafsson [26] (Pediatr Pulmonol 36:34–42)
He
28 Infants (3 to 28 mo) Full term Mass spectrometer 9.3 NR NR 9.1 to 9.6 NR Chakr [65]
18 Children Mass spectrometer 6.50 0.45 NR NR NR Aljassim [66]
18 Children Mass spectrometer 6.54 0.47 NR NR NR Aljassim [66]
MES = modified emission spectrophotometer, NR = not reported, VT = tidal volume. * signifies median or IQR.
a Exhalyzer D (Ecomedics AG, Duernten, Switzerland).
b Spiroson(R), Ecomedics AG, Duernten, Switzerland.
c EasyOne Pro, MBW Module (ndd Medizintechnik AG, Zurich, Switzerland) plus addition of CO2 analyser (DUET ETCO2 Module, Welch Allyn OEM Technologies, Beaverton, OR, USA).
d Modiﬁed Innocor (Innovision, Odense, Denmark).
e Medscience 505 (Medscience Electronics, Inc., St. Louis, MO, USA).
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occurs early in CF lung disease and is not detected with traditional
spirometric measures such as FEV1. LCI has a significant and
growing evidence base which indicates that its clinimetric pro-
perties are positive and more useful than traditional spirometric
parameters in early or mild disease. LCI has a well-established and
acceptable safety and feasibility profile throughout the spectrum of
ages and severities of CF lung disease. The test performance has
been standardised in a recent ERS/ATS guideline [14]. The use of
LCI in multicentre clinical trials will be facilitated in the near future
by the standardisation efforts such as those by the ECFS-CTN
Standardisation Committee: agreed standard operating procedures
for performance of the measurement and for training and cer-
tification procedures, central quality control and the availability of
central over-reading. The availability of commercial systems and
systems that do not require specific gases such as SF6 may also
boost more general use and facilitate standardisation between
centres in large scale trials.
3.4.2. Question 2: For what kind of therapeutic trial is LCI
appropriate? (therapeutic aim; phase of trial, target population,
number of patients involved, number of sites involved)
At present LCI has mainly been used in phase two trials
evaluating therapeutic benefit. A recent phase two trial of
ivacaftor in patients with mild lung disease showed that LCI
was more responsive to treatment than FEV1 [9]. A post-hoc
power analysis demonstrated a much lower number of patients
needed when using LCI rather than FEV1 as primary outcome.
Since this was a multicentre trial, it also demonstrates the
feasibility of using LCI across centres in different countries.
The accumulating evidence indicates that, in addition to phase
two trials, LCI is becoming applicable to phase three trials.
Given LCI's greater sensitivity than FEV1, it is especially
appropriate for use in phase three trials in small populations
(e.g. rare mutations), young children, patients with mild lung
disease, or to reduce the number of subjects needed.
3.4.3. Question 3: Within what timeline can change be expected
and what treatment effect can be considered clinically significant?
Available studies have not addressed how quickly LCI changes
after an intervention. The biological mechanisms underlying
abnormally raised LCI are thought to be (a) regional airway
endoluminal obstruction by retained secretions, (b) regional airway
obstruction due to mucosal airway inflammation and (c) regional
remodelling/fibrosis/destruction of airways. Mechanisms (a) and
(b) are amenable to change over days and improvements in LCI
following treatment of acute CF exacerbations have been
documented. A raised LCI might also have an irreversible part
related to structural abnormalities (c).
The treatment effect that can be considered clinically significant
should be larger than the difference in LCI seen between repeat
measurements without intervention or change in clinical status. In
healthy children and using SF6 as inert gas and mass spectrometer
as analyser, the CoR was 0.74 or 11% of the baseline value [39].
When using nitrogen washout and a commercial set-up, CoR was
0.6 in healthy children and 0.96 in children with CF [32]. For more
data on test repeatability we refer to Table E2.
3.4.4. Question 4: What studies are needed to further define
LCI in CF patients and its potential as a surrogate marker?
1. Clinical relevance: variability of LCI in preschool children
and infants. Correlation of LCI with clinical outcome
parameters such as time to pulmonary exacerbation. Use of
LCI in a multicentre setting to study treatment benefit in
preschool children and infants. Longitudinal evolution from
birth in a large cohort of CF patients.
2. Methodology: further comparisons of LCI measured according
to the recent consensus but using the different possible set-ups;
normative ranges and CoR across ages and for all techniques.
3. Additional information compared to other outcome param-
eters: correlation with regional ventilation abnormalities as
defined by imaging (e.g. hyperpolarized helium). Ideally
these studies should be interventional (e.g. before and after
treatment). Further correlations with inflammatory markers
in bronchoalveolar lavage or/and sera.
4. Conclusion
This document provides an overview of the work of the
ECFS-CTN Standardisation Committee on LCI. A systematic
review of the clinimetric properties of LCI demonstrates its
reliability, validity and responsiveness. LCI also has an attractive
feasibility profile. It is particularly useful for multicentre trials in
young children with CF and in patients with early or mild CF
lung disease when FEV1 is within normal range. This is the first
article to collate the literature on LCI and CF in this manner and
provides a strong evidence base to support the use of LCI in
clinical trials in CF.
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